Owkin is a French-American startup created in 2016, that uses artificial intelligence to find the right treatment for every patient. Our focus is to use AI to discover and develop better treatments for unmet medical needs, starting with the fight against cancer.
We use AI to identify new drug candidates, de-risk and accelerate clinical trials and build diagnostic tools that improve patient outcomes.
Using federated learning, a pioneering collaborative AI framework, Owkin enables medical researchers and biopharma partners to unlock valuable insights from siloed datasets, while protecting patient privacy and securing proprietary data.
Owkin’s team is now over 230 strong, with world-leading expertise across machine learning, federated learning and biology, and a Scientific Advisory Board consisting of some of the world's best specialists in numerous disease areas and a wide network of research partners.
Owkin has offices in Paris, Boston, Nantes, London, New York, and Geneva.
Federated data networks, biostatistics, diagnostic tools, biomarkers, drug target identification, drug combination, drug repurposing, external control arms, covariate adjustment, genomics, spatial omics, machine learning, federated learning, on-premise and cloud-based infrastructure solutions, artificial intelligence, data FAIRification, health data architecture, data harmonization, data management, data security and privacy.